Oxford Biomedica Share Discussion Threads

[stocktastic] 21/10/2022 07:43

Did someone say OXB may have to acquire the rest of thr AAV asset?
Is that why the $25m loan uplift?

Is that why the share price is down?

[harry s truman] 20/10/2022 21:46

Definitely worth two and a half minutes of anyone's time



Professor Hill saying that he wants to repeat the covid exercise and mass produce hundreds of millions of doses at a few dollars each.

Surely a few words there inspired by Elwood and Jake Blues wanting to get the old band back together?

[steeplejack] 20/10/2022 19:36

Yes,you might be right.£2 is possible.If you look at the US markets (i'm reluctant to take the UK markets as totally representative just now) brokers are systematically doing the rounds and lowering price targets and recommendations for those stocks that are still showing good gains compared with 2-3 years ago.They've fallen but can be regarded as a source of cash,offering a profit taking exercise of sorts.Despite falls,equity markets have yet to capitulate (or 'panic' as you say) and one senses its coming especially since the geopolitical backcloth remains dire.I quit trying to finesse the falls months ago.The S&P 500 is still on a multiple of over 20.

[stocktastic] 20/10/2022 17:00

Watching this stock for 18 years, it almost always spikes down before a move up. So at some point, there will be a good entry. Almost as if an influential, well informed 'friend of holders' drives out stops before pumping it up

Trouble is, I dont see any stocks as a bargain until the markets get a proper panic crash in

200p looks a firmer floor to me, chartwise

[dominiccummings] 20/10/2022 14:44

"When he joined, there was only one woman on the board. Now there are three."

Well we know what the problem is then.....

[harry s truman] 20/10/2022 13:36

Breaking news - Liz Truss resignation: PM 'set to quit' - watch statement live

So we get Rishi then, the man who spent the Bank of England (£450bn and counting on covid measures). I'm sure this will end well.

[harry s truman] 20/10/2022 13:06

For anyone who didn't read it at the time, a brief reminder of who Roch is



It's quite a cv.

[gigabit] 20/10/2022 12:01

Agreed.

In 2020 a new Chairman was appointed. In 2021 some poor decisions resulted in the highly effective CEO 'retiring'. In January 2022 the Chairman was crowned as Interim CEO. It's been downhill all the way since then. A bit of a coincidence?

It's been 10 months since Dawson was replaced.I can't see a top-class CEO taking the job at OXB while the Board composition remains as it is but the share price would certainly bounce back if that happened.

[harry s truman] 20/10/2022 11:57

OXB proved in 2021 that they could make serious sums of money with just 3 of their bioreactors at not for commercial rates - which is the point which people keep making about malaria (for example) should OXB announce that is what the bioreactor which Serum has reserved will be doing for the next 10 years.

For what it's worth I agree with your (steeplejack) point of yesterday that OXB will likely get bought out now. We are now (imho) just too much of a bargain to be ignored for any large company with a gene therapy / viral vector requirement.

Astra paid 6.3x the depressed share price of another (smaller) vector play recently and I suspect that similar here for OXB would have most PIs resigned to it, but of course it all depends upon what Serum, Vulpes, Novo Nordisk and such are willing to take.

[dominiccummings] 20/10/2022 11:56

But wasn't the projections of cash flow provided at the last half year really rather solid and reassuring steeplejack?

[steeplejack] 20/10/2022 11:41

Except that this time round some sort of sanity is returning to the markets.Cryptocurrencies have fallen sharply and private investor speculation has dropped markedly.Companies making serious sums of money ie resource stocks like Shell,Conoco,RTZ are performing well and reliably while companies making little to no money with cash flow problems are in the doldrums,Dear old Warren would natter about tides going out no doubt.The deleveraging in equity markets is intense and,with interest rates on the rise,will prove enduring.

[harry s truman] 20/10/2022 11:23

For some reason I keep thinking about the dot.com boom when lastminute.com was famously beating British Steel for market cap at a time when the newly floated company had the turnover of a medium sized pub.

Sometimes it all is just a bit mad.

[harry s truman] 20/10/2022 11:19

I realise that OXB have an aversion to trading statements as they can often signal a bit of desperation, but I'm hoping that OXB take the opportunity to tuck a very brief one into our next piece of expected news.

General political chaos and post covid reaction economics aside, there's something very wrong with market perception where a company can be worth £6 or £7 per share through all of 2019 (before any of us had even heard of covid) and yet today with with the list below of everything besides the covid pandemic work which has happened since 2019 we are worth less than half the 2019 average price.

Oxford Biomedica PLC License & Supply Agreement with Juno Therapeutics - since expanded
First 4 suites approved for use in OxBox
Kymriah (Novartis CAR-T) in more indications
Deal With Beam Therapeutics For LentiVector
Deal With PhoreMost Team For Next-Gen Cell Therapy Development
OXB signs Agreement with Boehringer Ingelheim - since expanded
Licence and Supply Agreement with Cabaletta Bio for LentiVector(R) Platform
Licence & Supply Agreement with Arcellx, Inc. for LentiVector(R) Platform for CAR-T Therapeutics
Oxford Biomedica Solutions signs agreement with new undisclosed partner for AAV platform
Oxford Biomedica signs Licence & Supply Agreement with new undisclosed partner for LentiVector(R) platform for late-stage clinical programme
Oxford Biomedica Signs Licence & Supply Agreement with (another) undisclosed New Partner for LentiVector(R) Platform for CAR-T Therapy
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable(TM) technology

[dominiccummings] 20/10/2022 09:36

No Managing Director and a part time Chairman/Acting MD can't help.

[gigabit] 20/10/2022 09:33

I believe this is a typical example of a company with an excellent product and inept management. The share price in no way represents the potential of the company, even if you ignore HST's hyperbole, but will remain depressed while the financial and strategic sides are seemingly poorly managed.

If the share price drops much more a critical point might be reached in relation to the loan the terms of which state 'includes the usual and customary provisions relating to mandatory prepayments, covenants and representations and warranties'. It would be usual for the covenants to include a warranty that the market capitalisation would remain above a specified level and failure to meet that could trigger an immediate repayment.

[marcusl2] 20/10/2022 08:30

"It's life, Jim, but not as we know it"

[badger60] 20/10/2022 04:11

It's a funny old game...innit. The 50 Mio quid worth of shares that SII purchased to upgrade the OxBox facility last year now becomes part of the collateral, along with the rest of what OXB owns, to cover the 50 Mio USD being lent by Oaktree, arguably to help keep OXB afloat.

[rrb] 19/10/2022 19:06

The move was most likely down to a guidance cut from Sartorius - a bioprocessing bellwether - which ended the day -18%. All the life sci stocks are down on this. OXB is seen more as a life sci play now with lenti manufacturing so important to revenues. I’m assuming that’s given market makers a reason to walk share price down (it was -7% on -50% average volume) and trigger stops.

[harry s truman] 19/10/2022 18:31

Rathean,

I seem to remember buying some shares at 1.5p and I'm pretty sure that there was one small placing at a penny, so I'm certain that it dropped lower than 3p in the past but I take your point.

I think we all know the current issues:-

1) Post coronavirus spending economy is a disaster with inflation 10%+ again today.

2) An awful lot of people who bought OXB last year did it after seeing reflected glory charlatans at our factory on the TV news and in the broadsheets. To them and to the hacks who wrote the stories then OXB was just a coronavirus stock with that being over now. You know that's not the case, but outside of us and these forums who do you think knows about our pipeline - and more importantly our prospects?

3) They used the windfall of the vaccine work to branch into AAV and another territory. That spend frightened a lot of people - including the Times, who as mentioned earlier seem for some bizarre reason to think we are out of financial necessity now in a redundancy situation.

What changes this perception can only be news, but if the £58m from the building sale is announced tomorrow then I think it at best steadies the ship.

I was pleased not to see it fall away further today when £3 was breeched. To my mind this suggests that the stops which people were hunting for weren't there, which is why it ended up closing at £3. Not great and a bit of a consolation prize, but until the expected news comes then I'll take it.